Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Colinz LaboratoriesBOM:531210 -4.47%59 PE Ratio (TTM) is 7.12 as of Aug. 22, 2026, which is 75% below its 10-year median of 28.17. GuruFocus rates BOM:531210 with a GF Score™ of 59/100 and a GF Value™ of ₹42.99 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 635 Drug Manufacturers companies, Colinz Laboratories ranks better than 90.08% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-22), Colinz Laboratories's share price is
₹74.20.
Colinz Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹10.42. Therefore, Colinz Laboratories's PE Ratio (TTM) for today is 7.12.
Good Sign:
Colinz Laboratories Ltd stock PE Ratio (=7.12) is close to 10-year low of 6.58.
The historical rank and industry rank for Colinz Laboratories's PE Ratio (TTM) or its related term are showing as below:
BOM:531210'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 6.58 Med: 28.17 Max: 126.23
Current: 7.12
During the past 13 years, the highest PE Ratio (TTM) of Colinz Laboratories was 126.23. The lowest was 6.58. And the median was 28.17.
BOM:531210's PE Ratio (TTM) is ranked better than 90.08% of 635
companies
in the Drug Manufacturers industry
Industry Median: 21.11
vs BOM:531210: 7.12
During the past 12 months, Colinz Laboratories's average EPS without NRIGrowth Rate was -8.10% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 39.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 53.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 25.50% per year.
During the past 13 years, Colinz Laboratories's highest 3-Year average EPS without NRI Growth Rate was 128.90% per year. The lowest was -18.70% per year. And the median was 19.95% per year.
Colinz Laboratories's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹9.53.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹10.42.
Colinz Laboratories (BOM:531210) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Colinz Laboratories PE Ratio (TTM) Related Terms
Colinz Laboratories PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Colinz Laboratories's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Colinz Laboratories's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Colinz Laboratories PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Colinz Laboratories's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Colinz Laboratories's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Colinz Laboratories's Share Price of today is ₹74.20.
Colinz Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Colinz Laboratories (BOM:531210) has a PE Ratio (TTM) of 7.12 as of Aug. 22, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Colinz Laboratories and its competitors. This is 75% below median its historical median of 28.17. Over the past decade, Colinz Laboratories' PE Ratio (TTM) has ranged from 6.58 to 126.23. According to the industry distribution chart, Colinz Laboratories ranks #63 out of 635 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Colinz Laboratories' PE Ratio (TTM) too high?
Colinz Laboratories' current PE Ratio (TTM) of 7.12 is 75% below median its 10-year median of 28.17. Over the past 10 years, this metric has ranged from a low of 6.58 to a high of 126.23. The Drug Manufacturers industry median PE Ratio (TTM) is 21.11. Colinz Laboratories' value of 7.12 is 66.3% below this industry median. Based on the distribution chart, Colinz Laboratories ranks #63 out of 635 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Colinz Laboratories has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' PE Ratio (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Colinz Laboratories ranks #63 out of 635 companies for PE Ratio (TTM). This places Colinz Laboratories in the top 10% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 21.11. Colinz Laboratories' value of 7.12 is 66.3% below this benchmark. Historically, Colinz Laboratories' own PE Ratio (TTM) has ranged from 6.58 to 126.23 over the past decade. While the company's 10-year median is 28.17 vs. the industry median of 21.11, Colinz Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.11, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Colinz Laboratories's current PE Ratio (TTM) of 7.12 is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Colinz Laboratories and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Colinz Laboratories's current PE Ratio (TTM) is 7.12, which is 75% below median its own 10-year median of 28.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹42.99, compared to a current price of ₹74.20 — trading 72.6% above its estimated fair value. The current PE Ratio (TTM) is 7.12, which is 75% below median its 10-year median of 28.17 and 66.3% below the Drug Manufacturers industry median of 21.11. Colinz Laboratories' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current PE Ratio (TTM) is 7.12 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Colinz Laboratories (BOM:531210) Overvalued in 2026?
Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued.
The current stock price of ₹74.20 is trading 72.6% above its estimated GF Value™ of ₹42.99.
GuruFocus considers Colinz Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:531210:
PE Ratio (TTM): 7.12 (75% below median its 10-year median of 28.17)
GF Value™: ₹42.99 vs. price of ₹74.20 (72.6% above fair value)
Industry Position: 66.3% below the Drug Manufacturers median (#63 of 635)
No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
59GF Score
Get the complete analysis for BOM:531210
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531210 has been successfully added to your 
